Navigation Links
Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
Date:4/24/2008

commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward- looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize TTP diagnostic products in 2008 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize TTP diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop TTP diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its TTP diagnostic products; (5) uncertainty of market acceptance of its TTP diagnostic products, inclu
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
2. Vermillion Receives Award From the Society of Gynecologic Oncologists
3. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
7. SuperGens MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
8. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges
9. Wayne State University and Oakwood Partner in New Device to Combat Congestive Heart Failure
10. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 17, 2014   Headquartered ... Inc. (OTC: GWPC) is a diversified company.  WholeHEALTH ... convenience of advanced technology and proven expertise of ... business of health and wellness.  WholeHEALTH Products, comprehensive ... doctors, clinics and healthcare centers, and 8 retail ...
(Date:11/18/2014)... , Nov. 18, 2014  Cardica, Inc. (Nasdaq: ... Cardica Board has approved management,s recommendation to shift ... of the MicroCutter XCHANGE® 30 surgical stapler to ... launch.  As a result, Cardica has temporarily suspended ... its latest iteration of the MicroCutter XCHANGE 30 ...
(Date:11/18/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the receipt of approval from the U.S. Food and ... IDEAL IMPLANT ® Saline-filled Breast Implant ... existing augmentation implants. The FDA approval of the IDEAL ... studies and data including a U.S. clinical trial that ...
Breaking Medicine Technology:WholeHEALTH Product Inc. to File FDA Emergency Use Approval (EUA) for PCR Rapid Ebola Test 2Cardica Announces Shift In Focus 2Cardica Announces Shift In Focus 3Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3
... 29, 2011 As small businesses struggle to afford ... concern that forthcoming Essential Health Benefits regulations could include ... to raise prescription drug costs, the Pharmaceutical Care ... (PBMs) administer drug benefits for thousands of small businesses ...
... JOLLA, Calif., Sept. 29, 2011 Synthetic Genomics Vaccines, ... next generation vaccines using genomic sequencing and synthetic genomic ... been appointed as president.  Dr. Farah brings extensive vaccine ... executive management experience in the biotechnology industry to SGVI. ...
Cached Medicine Technology:Some Essential Benefits Rules Could Worry Small Businesses 2Synthetic Genomics Vaccines, Inc. Hires Vaccine Executive Sammy J. Farah as President 2
(Date:11/18/2014)... TX (PRWEB) November 18, 2014 ... advice and insights, adding to the company's reputation ... Explore everything the blog has to offer at ... through all the information concerning the Affordable Care ... blog aims to inform the public about a ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... An experimental antibody drug could prove effective at lowering ... effects with cholesterol-lowering statin medications. That,s the conclusion ... Heart Association annual meeting in Chicago. The drug, ... most widely used alternative to statins, Zetia, said lead ...
(Date:11/18/2014)... Women who started smoking at a young age may ... a new study suggests. About 29 percent of ... suspected as a risk factor for severe menstrual pain, ... new study said. The researchers analyzed data from ... women,s health in Australia. About 14 percent of the ...
(Date:11/18/2014)... GA (PRWEB) November 18, 2014 ... focused on using the telehealth platform to bring ... Because of this passion, GPT created Global Partnership ... utilizing GPT’s already existing telehealth network. GPTM ... orphanages, hospitals overseas, and disaster relief organizations. ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Sometimes at ... situations with print devices like unforeseen error messages or ... don't have time to find another printer and they ... The IT department is likely tied up with other ... , That’s where Electronic Systems, Inc. (ESI) ...
Breaking Medicine News(10 mins):Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2
... Researchers at the University of Florida and Metagenics Inc. today ... combined with a low-glycemic, Mediterranean-style diet is almost twice as ... risk factors for cardiovascular disease, the leading cause of death ... medical food UltraMeal PLUS 360 is 40 percent more likely ...
... May 19 (HealthDay News) -- Summer fun can take a ... a common infection that accounts for almost $500 million in ... report. Swimmer,s ear results in 2.4 million doctor ... average of $200, according to the report from the U.S. ...
... FL (May 19, 2011)Researchers from the University of Miami (UM) ... different teaching models for children with Autism Spectrum Disorder (ASD). ... the fidelity of treatment models for preschoolers with autism. ... the journal Research in Autism Spectrum Disorders . ...
... ARBOR, Mich. A primary reason that head and neck ... chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive ... Indian spice curcumin can help cells overcome that resistance. ... head and neck cancer cell lines, they were able to ...
... have been diagnosed with poor sperm quality and who are ... Researchers have found that while cell phone use appears to ... may also lead to low sperm quality and a decrease ... puzzling," says Rany Shamloul, a postdoctoral fellow in the Department ...
... Crohn,s patients in a research study at Penn ... a chronic inflammatory condition of the gastrointestinal tract ... loss. Treatments for Crohn,s disease are designed to ... rare but serious side effects, including infections and ...
Cached Medicine News:Health News:Breakthrough medical food reverses risk of heart disease and diabetes 2Health News:Breakthrough medical food reverses risk of heart disease and diabetes 3Health News:Swimmer's Ear Costs Up to $500 Million a Year in U.S. 2Health News:Validating preschool programs for children with autism 2Health News:Curcumin compound improves effectiveness of head and neck cancer treatment, U-M study finds 2Health News:Use of naltrexone reduces inflammation in Crohn's patients 2
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
... Immunoassay Plus Control is a ... in today's busy immunoassay laboratory. ... this human serum based control ... separate control products for immunoassay ...
... The Vidiera NsD Nucleic Sample Detection ... acids, post amplification. The new platform ... by capillary electrophoresis (CE), with software features ... and flexibility. Vidiera NsD has the ...
Medicine Products: